The TREAT-NMD duchenne muscular dystrophy registries: Conception, design, and utilization by industry and academia

Catherine L. Bladen, Karen Rafferty, Volker Straub, Soledad Monges, Angélica Moresco, Hugh Dawkins, Anna Roy, Teodora Chamova, Velina Guergueltcheva, Lawrence Korngut, Craig Campbell, Yi Dai, Nina Barišić, Tea Kos, Petr Brabec, Jes Rahbek, Jaana Lahdetie, Sylvie Tuffery-Giraud, Mireille Claustres, France LeturcqRabah Ben Yaou, Maggie C. Walter, Olivia Schreiber, Veronika Karcagi, Agnes Herczegfalvi, Venkatarman Viswanathan, Farhad Bayat, Isis de la caridad Guerrero Sarmiento, Anna Ambrosini, Francesca Ceradini, En Kimura, Janneke C. van den Bergen, Miriam Rodrigues, Richard Roxburgh, Anna Lusakowska, Jorge Oliveira, Rosário Santos, Elena Neagu, Niculina Butoianu, Svetlana Artemieva, Vedrana Milic Rasic, Manuel Posada, Francesc Palau, Björn Lindvall, Clemens Bloetzer, Ayşe Karaduman, Haluk Topaloǧlu, Serap Inal, Piraye Oflazer, Angela Stringer, Andriy V. Shatillo, Ann S. Martin, Holly Peay, Kevin M. Flanigan, David Salgado, Brigitta von Rekowski, Stephen Lynn, Emma Heslop, Sabina Gainotti, Domenica Taruscio, Jan Kirschner, Jan Verschuuren, Kate Bushby, Christophe Béroud, Hanns Lochmüller

Research output: Contribution to journalArticle

71 Citations (Scopus)


Duchenne muscular dystrophy (DMD) is an X-linked genetic disease, caused by the absence of the dystrophin protein. Although many novel therapies are under development for DMD, there is currently no cure and affected individuals are often confined to a wheelchair by their teens and die in their twenties/thirties. DMD is a rare disease (prevalence <5/10,000). Even the largest countries do not have enough affected patients to rigorously assess novel therapies, unravel genetic complexities, and determine patient outcomes. TREAT-NMD is a worldwide network for neuromuscular diseases that provides an infrastructure to support the delivery of promising new therapies for patients. The harmonized implementation of national and ultimately global patient registries has been central to the success of TREAT-NMD. For the DMD registries within TREAT-NMD, individual countries have chosen to collect patient information in the form of standardized patient registries to increase the overall patient population on which clinical outcomes and new technologies can be assessed. The registries comprise more than 13,500 patients from 31 different countries. Here, we describe how the TREAT-NMD national patient registries for DMD were established. We look at their continued growth and assess how successful they have been at fostering collaboration between academia, patient organizations, and industry.

Original languageEnglish
Pages (from-to)1449-1457
Number of pages9
JournalHuman mutation
Issue number11
Publication statusPublished - Nov 1 2013



  • DMD
  • Disease registries
  • Duchenne muscular dystrophy
  • Rare disease

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Bladen, C. L., Rafferty, K., Straub, V., Monges, S., Moresco, A., Dawkins, H., Roy, A., Chamova, T., Guergueltcheva, V., Korngut, L., Campbell, C., Dai, Y., Barišić, N., Kos, T., Brabec, P., Rahbek, J., Lahdetie, J., Tuffery-Giraud, S., Claustres, M., ... Lochmüller, H. (2013). The TREAT-NMD duchenne muscular dystrophy registries: Conception, design, and utilization by industry and academia. Human mutation, 34(11), 1449-1457.